These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 10498572)
1. Hemochromatosis and vitamin C. Herbert V Ann Intern Med; 1999 Sep; 131(6):475-6. PubMed ID: 10498572 [No Abstract] [Full Text] [Related]
2. [Myocardiopathy caused by iron deposition. Treatment with chelating agents]. Rodríguez Reguero JJ; Iglesias Cubero G; Espolita Santos A; López de la Iglesia JM; Enríquez Martín J; Tomás Mauri J; López-Negrete L Rev Esp Cardiol; 1985; 38(5):356-7. PubMed ID: 4081244 [No Abstract] [Full Text] [Related]
3. [Effect of desferrioxamine B and 2-(beta-aminoethoxy)cyclohexylaminetetraacetate in experimental hemochromatosis in rats and in primary hemochromatosis of man]. Bohne F; Lessmann J Arzneimittelforschung; 1969 Jun; 19(6):944-7. PubMed ID: 5820039 [No Abstract] [Full Text] [Related]
4. [The treatment of post-transfusional hemochromatosis with chelating agents]. Delvaux D; Andrien JM; Fillet G Rev Med Liege; 1981 Jun; 36(11):477-80. PubMed ID: 6789438 [No Abstract] [Full Text] [Related]
5. Iron metabolism and chelation therapy in hemosiderosis. Graziano JH Curr Top Hematol; 1978; 1():127-50. PubMed ID: 400529 [No Abstract] [Full Text] [Related]
6. Chelation therapy for iron overload. Nutr Rev; 1980 May; 38(5):185-7. PubMed ID: 7207885 [No Abstract] [Full Text] [Related]
7. Vitamin C, desferrioxamine and iron loading anemias. Van der Weyden MB Aust N Z J Med; 1984 Oct; 14(5):593-5. PubMed ID: 6597704 [No Abstract] [Full Text] [Related]
8. [Hemochromatosis in the age of genetics]. Buffet C Presse Med; 2007 Sep; 36(9 Pt 2):1269-70. PubMed ID: 17560763 [No Abstract] [Full Text] [Related]
9. [Further experiences with iron-chelating therapy (desferrioxamine and ascorbic acid) in siderochromatosis and Cooley's disease]. Cartei G; Cazzavillan M; Chisesi T; Battista R; Barbui T; Dini E Minerva Med; 1978 Mar; 69(13):811-21. PubMed ID: 643223 [No Abstract] [Full Text] [Related]
10. [Idiopathic hemochromatosis. Therapeutics]. Pergola F Presse Med (1893); 1967 May; 75(24):1221-2. PubMed ID: 4960744 [No Abstract] [Full Text] [Related]
11. Treatment of primary hemochromatosis with deferoxamine. Young N; Henry W; Nienhuis AW JAMA; 1979 Mar; 241(11):1152-4. PubMed ID: 762769 [No Abstract] [Full Text] [Related]
12. Effect of ascorbic acid on desferrioxamine-induced urinary iron excretion in idiopathic hemochromatosis. Conte D; Brunelli L; Ferrario L; Mandelli C; Quatrini M; Velio P; Bianchi PA Acta Haematol; 1984; 72(2):117-20. PubMed ID: 6437113 [TBL] [Abstract][Full Text] [Related]
17. Chelating agents in medicine. Br Med J; 1971 May; 2(5756):270-2. PubMed ID: 4102017 [No Abstract] [Full Text] [Related]
18. Clinical usefulness of iron chelating agents. Waxman HS; Brown EB Prog Hematol; 1969; 6():338-73. PubMed ID: 4976246 [No Abstract] [Full Text] [Related]
19. Ascorbic acid status in idiopathic hemochromatosis. Brissot P; Deugnier Y; Le Treut A; Regnouard F; Simon M; Bourel M Digestion; 1978; 17(6):479-87. PubMed ID: 710734 [TBL] [Abstract][Full Text] [Related]